Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?

No abstract is available for this paper.

• Publication year

  1994

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/0959-8049(94)00423-3PMID 7857699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Literature Review

  2006cited by this paper
• The effect of verapamil on the pharmacokinetics of adriamycin

  2004cited by this paper
• Effects of verapamil on the pharmacokinetics of daunomycin in the rat

  2004cited by this paper
• Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

  1994cited by this paper
• Multidrug Resistance: Clinical Opportunities in Diagnosis and Circumvention

  1994cited by this paper
• Paclitaxel (Taxol)

  1994cited by this paper
• Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.

  1993cited by this paper
• Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

  1993cited by this paper
• Modulation of multidrug resistance: at the threshold.

  1993cited by this paper
• P glycoprotein (P-gp) and drug resistance--time for reappraisal?

  1993cited by this paper
• Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.

  1993cited by this paper
• Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene

  1993cited by this paper
• Clinical trials of agents that reverse multidrug resistance. A literature review

  1993cited by this paper
• Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicity

  1992cited by this paper
• Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

  1992cited by this paper
• Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia.

  1991cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Clinical trials of agents that reverse multidrug-resistance.

  1989cited by this paper
• Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts.

  1989cited by this paper
• Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

  1985cited by this paper

• Preparation and Characterization of Stable Nanoliposomal Formulation of Fluoxetine as a Potential Adjuvant Therapy for Drug-Resistant Tumors

  2014cites this paper
• Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.

  2012cites this paper
• Role of xenobiotic efflux transporters in resistance to vincristine.

  2008cites this paper
• Drug Resistance The Clinical Perspective

  2007cites this paper
• Modulation der Zytostatikawirkung und -resistenz

  2006cites this paper
• Nachweis und Modulation der P-Glykoprotein-vermittelten Multidrugresistenz bei akuter myeloischer Leukämie in vitro

  2005cites this paper
• Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo

  2005cites this paper
• Pharmacokinetic Optimisation of Treatment with Oral Etoposide

  2004cites this paper
• Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.

  2001cites this paper
• A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance

  2000cites this paper
• Expresión inmunohistoquímica de glicoproteína P como factor pronóstico en sarcomas óseos

  2000cites this paper
• Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.

  1999cites this paper
• 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.

  1999cites this paper
• Cytokine-mediated reversal of multidrug resistance

  1998cites this paper
• High-dose cyclosporin withetoposide -toxicity and pharmacokinetic interaction inchildren withsolid

  1998cites this paper
• High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.

  1998cites this paper
• Clinically relevant drug-drug interactions in oncology.

  1998cites this paper
• Multiple Drug Resistance in Cancer 2

  1998cites this paper
• Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

  1997cites this paper
• Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.

  1997cites this paper
• Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro.

  1997cites this paper
• Neue Entwicklungen in der Tumortherapie

  1996cites this paper
• Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.

  1996cites this paper
• Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

  1996cites this paper
• What have we learnt thus far from mice with disrupted P-glycoprotein genes?

  1996cites this paper
• Multidrug resistance reversal in childhood malignancies--potential for a real step forward?

  1996cites this paper
• The clinical pharmacology of etoposide: an update.

  1996cites this paper
• Multidrug resistance and the role of P-glycoprotein knockout mice.

  1995cites this paper
• Decreased potency of MDR‐modulators under serum conditions determined by a functional assay

  1995cites this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cites this paper